Moderna, Inc. (NASDAQ:MRNA) traded at $63.67 at last check on Monday, Sep 14, making an upward move of 7.3% on its previous day’s price.

Looking at the stock we see that its previous close was $59.34 and the beta (5Y monthly) reads 0. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, MRNA has a high of $95.21 and a low of $13.53. The company’s stock has gained about -6.13% over that past 30 days.

There have been no upward or downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the MRNA stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of 50% Buy.

Based on estimates by 15 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 2 have rated the Moderna, Inc. (MRNA) stock as a Hold, while 12 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas 1 suggests the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the MRNA stock currently stands at 0, and the current price level is -1.58% off its SMA20 and -9.35% from its 50-day simple moving average. The RSI (14) is pointing at 46.18 while the volatility over the past week is 5.78% and drops to 5.52% over the past one month. The beta value is 0, while the average true range (ATR) is currently pointing at 3.88. The average price target for the stock over the next 12 months is $92.07, with the estimates having a low of $41 and a high of $134. These price ends are -35.61% and +110.46% off the current price level respectively, although investors could be excited at the prospect of a +44.5% if the MRNA share price touches on the median price of $92.

Let’s briefly compare Moderna, (MRNA) stock to its peers. We find that today’s price change of +7.3% and +281.03% over the past 12 months for MRNA betters that of Amgen Inc (AMGN), which has seen its stock price rise 1.46% in the latest trading session and is +26.23% over the last one year. Another of its peers Bristol-Myers Squibb Company (BMY) has climbed 1.2% today, and is +20.78% up over the past year, while Gilead Sciences Inc (GILD) is also up 7.3% yet its price remains in the green at 281.03% over the same period. Amgen has a P/E ratio of 20.16 compared to Moderna,’s 0 and Bristol-Myers 0. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 1.27% and 1.18%, respectively, in early deals.